AKT1 and breast carcinoma: Among the molecular mechanisms involved in the acquisition of endocrine resistance, a switch from steroid signaling to growth factor signaling pathways has been the focus of recent studies, which have demonstrated the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and/or mitogen-activated protein kinase (MAPK) pathways, both in breast cancer cell lines and in breast tumors [2-8].